ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. NanOss® Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3™ Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.
“We are very excited to launch these two bone graft solutions,” said Brian K. Hutchison, president and chief executive officer of RTI Surgical. “NanOss Bioactive 3D, a synthetic bone graft, and map3 Cellular Allogeneic Bone Graft, a human tissue bone graft, showcase the broad portfolio of surgical implants offered by RTI Surgical.”
nanOss® Bioactive 3D
The next-generation nanOss Bioactive 3D is an innovative solution that allows for precise placement of the graft into bony defects for a wide range of extremity and trauma surgical procedures. This advanced bone graft features a semi-rigid three dimensional scaffold consisting of porous hydroxyapatite granules suspended within a porous gelatin-based foam matrix, designed to support the body’s natural bone formation process. When hydrated, nanOss Bioactive 3D becomes formable and moldable allowing the implant to conform to the defect site. NanOss Bioactive 3D consists of nano-structured crystals which have extremely high surface area providing more cell attachment sites for osteoclasts and osteoblasts resulting in potential for improved mineralization, remodeling and bone formation.
“NanOss Bioactive 3D is easy to use and has a rigid structure that does not fall apart,” said Edgardo Rodriguez, DPM, director of the Chicago Foot and Ankle Deformity Correction Center. “Its high surface area makes it a very favorable and suitable osteoconductive scaffold.”
map3™ Cellular Allogeneic Bone Graft
Map3 chips allograft is comprised of cortical cancellous chips, demineralized bone matrix and viable adult stem cells based on the multipotent adult progenitor (MAPC®) cell technology. Map3 supplies the three essential elements necessary for bone formation in a single allograft. MAPC-class cells, a specific type of stem cell, are known to have osteogenic and angiogenic properties, important in supporting the bone healing process. The implant is designed for ease of use, has been processed to achieve optimal handling and is ideal for graft packing and filling bony defects.
“Map3 is an exciting new cellular allogeneic bone graft,” said Samuel B. Adams Jr., MD, orthopedic surgeon, Duke University Medical Center, Durham, NC. “Not only is it osteoconductive, osteoinductive and osteogenic but the MAPC-based technology incorporated into map3 adds proven angiogenic properties. This unique and important feature makes map3 my preferred bone graft.”
To learn more about map3, visit www.map3.com, a website designed to educate surgeons and patients about map3 and MAPC-based technology. The website explores the advanced bone graft and its use in repairing bone injuries, as well as frequently asked questions.
NanOss Bioactive 3D and map3 Cellular Allogeneic Bone Graft are available from RTI Surgical. For more information please visit www.rtisurgical.com.
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to advancing science, safety and innovation, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit http://www.rtix.com/.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). In addition, these statements are subject to risks associated with the Pioneer’s financial condition, business and operations and the integration of Pioneer’s business with ours. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.
